Related Experiment Videos
[Hypertension--the status in Austria]
1Institut für Hypertoniker, Wien. hypertonie@eunet.at
Wiener Medizinische Wochenschrift (1946)
|March 18, 2000
Insights
Hypertension affects 25-30% of Austrians, with many unaware and undertreated. Even physicians have high rates of elevated blood pressure, with poor treatment outcomes and limited monotherapy effectiveness.
Area of Science:
- Cardiology
- Public Health
Context:
- Hypertension prevalence in Austria is high, affecting 25-30% of the population.
- A significant portion of individuals with hypertension are undiagnosed or inadequately treated.
- Physician hypertension rates are also elevated, with suboptimal management.
Purpose:
- To highlight the critical gaps in hypertension awareness, diagnosis, and treatment in Austria.
- To underscore the challenges in achieving normotension even with treatment.
- To identify the limitations of current hypertension management strategies, including monotherapy.
Summary:
- Approximately 25-30% of the Austrian population has hypertension.
- Nearly half of hypertensive individuals are unaware of their condition.
- Only one-third receive treatment, with only 10% achieving normotension.
- Physician hypertension is prevalent, with poor diagnosis and treatment rates.
- Current treatments are largely monotherapy and show unsatisfactory results.
Impact:
- Reveals a significant public health burden due to uncontrolled hypertension in Austria.
- Suggests a need for improved screening, diagnostic protocols, and treatment guidelines.
- Indicates a critical need for more effective hypertension management strategies and patient education.
Abstract:
In Austria approximately 25-30% of the population have hypertension. Nearly half of them is not aware of their condition. Only one third undergoes treatment. Of those who are treated only 10% reach normotension. Among physicians these values are even worse: nearly two thirds show an elevated pressure, but only 20% of them are treated. Treatment itself is unsatisfactory: nearly 100% of patients receive a monotherapy only.